| Gene symbol | EPHA2 | Synonyms | ARCC2, CTPA, CTPP1, CTRCT6, ECK | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1p36.13 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | EPH receptor A2 | ||||
| Gene symbol | KRAS | Synonyms | C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | KRAS proto-oncogene, GTPase | ||||
| GTO ID | GTC3253 |
| Trial ID | NCT05631899 |
| Disease | Solid Tumor |
| Altered gene | KRAS|EPHA2 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-DC cell |
| Treatment | KRAS-EphA-2-CAR-DC |
| Co-treatment | anti-PD-1 antibody+anti-CTLA4 antibody |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Combination of CAR-DC Vaccine and Anti-PD-1 Antibody in Local Advanced/Metastatic Solid Tumors |
| Year | 2022 |
| Country | China |
| Company sponsor | Chinese PLA General Hospital |
| Other ID(s) | CHN-PLAGH-BT-074 |
| Cohort1: anti-PD-1 antibody+anti-CTLA4 antibody | |||||||||||
|
|||||||||||
| Cohort2: anti-PD-1 antibody | |||||||||||
|
|||||||||||